ReviewWorld journal of diabetes2015
Type 1 diabetes: A predictable disease.
Review in World journal of diabetes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 115 citations in OpenAlex.
- Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO-Peds trial.Diabetes, obesity & metabolism · 2023Trial
- Trial
- ST8Sia6 overexpression protects pancreatic β cells from spontaneous autoimmune diabetes in nonobese diabetic mice.The Journal of clinical investigation · 2025Article
- Leveraging Underutilized Sri Lankan Fruits in the Fight against Autoimmune Disorders.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2025Review
- Evaluation of Taste Perception and Olfactory Function in Adolescents in Relation to the Duration of Type 1 Diabetes.Pediatric diabetes · 2025Article
- Mechanisms of insulin resistance in type 1 diabetes mellitus: A case of glucolipotoxicity in skeletal muscle.Journal of cellular physiology · 2024Review
- Enzyme Inhibitors as Multifaceted Tools in Medicine and Agriculture.Molecules (Basel, Switzerland) · 2024Review
- Evaluation of genetic association between celiac disease and type 1 diabetes.Journal of diabetes and metabolic disorders · 2024Article
- An Insulin-Chromogranin A Hybrid Peptide Activates DR11-Restricted T Cells in Human Type 1 Diabetes.Diabetes · 2024Article
- Evidence from clinical trials on high-risk medical devices in children: a scoping review.Pediatric research · 2024Article
- Comparative Analysis of COVID-19 Outcomes in Type 1 and Type 2 Diabetes: A Three-Year Retrospective Study.Medicina (Kaunas, Lithuania) · 2024Article
- Relation between the Epicardial Fat Thickness and the Cardiac Conduction System in Children and Adolescents with Diabetes.Hormone research in paediatrics · 2024Article
- Oral delivery of bi-autoantigens by bacterium-like particles (BLPs) against autoimmune diabetes in NOD mice.Drug delivery · 2023Article
- Medication profiling in women with type 1 diabetes highlights the importance of adequate, guideline-based treatment in low-risk groups.Scientific reports · 2023Article
- Real-life data of hypoglycemic events in children and adolescents with type 1 diabetes.BMJ open diabetes research & care · 2023Article
- Food contaminants and potential risk of diabetes development: A narrative review.World journal of diabetes · 2023Review
- Advances in Immunotherapeutic Approaches to Type 1 Diabetes.International journal of molecular sciences · 2023Article
- Oral delivery of the intracellular domain of the insulinoma-associated protein 2 (IA-2ic) by bacterium-like particles (BLPs) prevents type 1 diabetes mellitus in NOD mice.Drug delivery · 2022Article
- Engineered Extracellular Vesicles in Treatment of Type 1 Diabetes Mellitus: A Prospective Review.Biomedicines · 2022Review
- Association between metabolic control and oral health in children with type 1 diabetes mellitus.BMC oral health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Type 1 diabetes (T1D) is an autoimmune disease characterized by loss of insulin producing beta cells and reliance on exogenous insulin for survival. T1D is one of the most common chronic diseases in childhood and the incidence is increasing, especially in children less than 5 years of age. In individuals with a genetic predisposition, an unidentified trigger initiates an abnormal immune response and the development of islet autoantibodies directed against proteins in insulin producing beta cells. There are currently four biochemical islet autoantibodies measured in the serum directed against insulin, glutamic decarboxylase, islet antigen 2, and zinc transporter 8. Development of islet autoantibodies occurs before clinical diagnosis of T1D, making T1D a predictable disease in an individual with 2 or more autoantibodies. Screening for islet autoantibodies is still predominantly done through research studies, but efforts are underway to screen the general population. The benefits of screening for islet autoantibodies include decreasing the incidence of diabetic ketoacidosis that can be life threatening, initiating insulin therapy sooner in the disease process, and evaluating safe and specific therapies in large randomized clinical intervention trials to delay or prevent progression to diabetes onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.